Market cap of Chimerix Inc. [CMRX] reaches 255.53M – now what?

Related

Chimerix Inc. [NASDAQ: CMRX] surged by $0.36 during the normal trading session on Tuesday and reaching a high of $2.64 during the day while it closed the day at $2.40. The company report on June 24, 2022 that Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolutions, Inc. (Emergent).

“This second international procurement contract highlights TEMBEXA’s important role as a medical countermeasure and the need to have these types of medicines in strategic stockpiles for all age groups,” said Mike Sherman, Chief Executive Officer of Chimerix. “With this new procurement, we are still on track to deliver the expected obligations associated with a potential U.S. Biomedical Advanced Research and Development Authority (BARDA) contract and initial delivery into the U.S. Strategic National Stockpile later this year.”.

Chimerix Inc. stock has also gained 2.56% of its value over the past 7 days. However, CMRX stock has declined by -52.19% in the 3 months of the year. Over the past six months meanwhile, it has lost -57.14% and lost -62.67% year-on date.

The market cap for CMRX stock reached $255.53 million, with 87.09 million shares outstanding and 78.75 million shares in the current float. Compared to the average trading volume of 4.66M shares, CMRX reached a trading volume of 35099650 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Chimerix Inc. [CMRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CMRX shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CMRX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Maxim Group have made an estimate for Chimerix Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 29, 2021. While these analysts kept the previous recommendation, Cowen raised their target price from $10 to $18. The new note on the price target was released on April 23, 2021, representing the official price target for Chimerix Inc. stock. Previously, the target price had yet another raise to $21, while Wedbush analysts kept a Outperform rating on CMRX stock.

The Average True Range (ATR) for Chimerix Inc. is set at 0.29, with the Price to Sales ratio for CMRX stock in the period of the last 12 months amounting to 425.88. The Price to Book ratio for the last quarter was 4.36, with the Price to Cash per share for the same quarter was set at 0.50.

CMRX stock trade performance evaluation

Chimerix Inc. [CMRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.56. With this latest performance, CMRX shares gained by 16.50% in over the last four-week period, additionally sinking by -57.14% over the last 6 months – not to mention a drop of -66.34% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CMRX stock in for the last two-week period is set at 56.35, with the RSI for the last a single of trading hit 59.87, and the three-weeks RSI is set at 52.37 for Chimerix Inc. [CMRX]. The present Moving Average for the last 50 days of trading for this stock 1.99, while it was recorded at 2.16 for the last single week of trading, and 4.68 for the last 200 days.

Chimerix Inc. [CMRX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Chimerix Inc. [CMRX] shares currently have an operating margin of -4573.52 and a Gross Margin at +76.35. Chimerix Inc.’s Net Margin is presently recorded at -8753.71.

Return on Equity for this stock declined to -244.64, with Return on Assets sitting at -187.02.

Chimerix Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.90 and a Current Ratio set at 4.10.

Chimerix Inc. [CMRX]: Insider Ownership positions

There are presently around $108 million, or 67.50% of CMRX stock, in the hands of institutional investors. The top three institutional holders of CMRX stocks are: OPALEYE MANAGEMENT INC. with ownership of 5,903,450, which is approximately 5.797% of the company’s market cap and around 0.80% of the total institutional ownership; BLACKROCK INC., holding 5,349,042 shares of the stock with an approximate value of $10.91 million in CMRX stocks shares; and RUBRIC CAPITAL MANAGEMENT LP, currently with $9.79 million in CMRX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Chimerix Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 54 institutional holders increased their position in Chimerix Inc. [NASDAQ:CMRX] by around 5,279,485 shares. Additionally, 58 investors decreased positions by around 3,631,288 shares, while 27 investors held positions by with 43,884,974 shares. The mentioned changes placed institutional holdings at 52,795,747 shares, according to the latest SEC report filing. CMRX stock had 19 new institutional investments in for a total of 2,689,052 shares, while 13 institutional investors sold positions of 780,102 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]